ProfileGDS5678 / 1438047_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 89% 87% 88% 90% 88% 90% 88% 88% 90% 90% 88% 89% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.9416289
GSM967853U87-EV human glioblastoma xenograft - Control 27.0773989
GSM967854U87-EV human glioblastoma xenograft - Control 36.6432687
GSM967855U87-EV human glioblastoma xenograft - Control 47.1112688
GSM967856U87-EV human glioblastoma xenograft - Control 57.2024390
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5748288
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.9358390
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.7666588
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8245988
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.203690
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.1327590
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.9096288
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.062689
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.9557889